Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma – guidance (TA680)

Lenalidomide is recommended as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults, only if the dosage schedule is 10 mg per day on days 1 to 21 of a 28‑day cycle.

National Institute for Health and Care Excellence